I like Coffee...
but i like this too:
CytoGenix Gene Silencing ssDNA Technology Patent Allowed in Europe and India
Business Wire - October 30, 2006 9:44 AM ET
CytoGenix, Inc. (CYGX:OB) has received notices of allowances for grant of patent applications covering the technology for expressing ssDNA In Vivo, from the Indian and European Community Patent Offices. These notices follow the previous notice of allowance for these applications from the Peoples Republic of China.
Filed in 1999 and 2000, these patents cover the company's single-strand DNA expression system covered by a US patent and by several patent applications in major world markets. Used in the company's Simplivir(TM) anti-herpes and CY303 anti inflammation products, an ssDNA gene silencing compound is active in reducing tumors in a melanoma experimental animal model.
Dr. Yin Chen, CytoGenix, Inc. Vice President, Chief Scientific Officer and a co-inventor of the single-strand DNA expression technology, states, "This is another step in our intellectual property strategy for this technology. These countries offer significant market opportunities and we are seeking appropriate licensees and partners."
About CytoGenix, Inc.: CytoGenix, Inc. is a Houston-based biopharmaceutical company that develops and markets innovative products and services based on its proprietary ssDNA expression technology. The company has developed a breakthrough synthetic process for large-scale production of high purity DNA at a fraction of the cost of traditional fermentation methods. CytoGenix currently has one issued US patent and 47 international or US pending patent applications claiming methods and materials in connection with this platform technology.
SAFE HARBOR: Except for statements of historical fact, the statements in this press release are forward-looking. Such statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include, but are not limited to, general economic conditions, risks associated with the acceptance of new products, competition, and other factors more fully detailed in the company's filings with the Securities and Exchange Commission. Additional information about CytoGenix and its technology is found on the website at www.cytogenix.com.
SOURCE: CytoGenix, Inc.
CytoGenix, Inc., Houston
Frank Vazquez, 713-789-0070
AI
